From a healthcare perspective, such approaches promoting healthy eating were estimated to be as or more cost-effective than many currently covered medical interventions, such as drug treatment for hypertension ($20,000/QALY) [53], use of statins for primary prevention ($37,000/QALY) [42], or addition of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to statins in patients with CVD ($414,000/QALY) [54] or heterozygous familial hypercholesterolemia ($503,000/QALY) [54]. The gene discussed is PCSK9; the disease is familial hypercholesterolemia.